Efficacy of co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes in a murine triple-negative breast cancer model

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clinicians. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal AJCACJFC. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   Google Scholar
• Erenpreisa J, Cragg MS. Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int. 2013;13(1):92. doi:10.1186/1475-2867-13-92.
   PubMedGoogle Scholar
• Ghahremani F, Shahbazi-Gahrouei D, Kefayat A, Motaghi H, Mehrgardi MA, Javanmard SH. AS1411 aptamer conjugated gold nanoclusters as a targeted radiosensitizer for megavoltage radiation therapy of 4T1 breast cancer cells. RSC Adv. 2018;8(8):4249–58. doi:10.1039/C7RA11116A.
   Web of Science ®Google Scholar
• Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010;1(2):109.
   PubMedGoogle Scholar
• Khanfir A, Lahiani F, Bouzguenda R, Ayedi I, Daoud J, Frikha M. Prognostic factors and survival in metastatic breast cancer: a single institution experience. Rep Pract Oncol Radiother. 2013;18(3):127–32. doi:10.1016/j.rpor.2013.01.001.
   PubMedGoogle Scholar
• Arpino G, Milano M, De Placido S. Features of aggressive breast cancer. Breast. 2015;24(5):594–600. doi:10.1016/j.breast.2015.06.001.
   PubMed Web of Science ®Google Scholar
• Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274(2):113–26. doi:10.1111/joim.12084.
   PubMed Web of Science ®Google Scholar
• Montano, D.J.J.o.O.M. and Toxicology. Chemical and biological work-related risks across occupations in Europe: a review. J Occup Med Toxicol. 2014;9(1):28.
   PubMedGoogle Scholar
• Stuckey AR, Onstad MA, Gynecology. Hereditary breast cancer: an update on risk assessment and genetic testing in 2015. Am J Obstetrics Gynecol. 2015;213(2):161–65.
   PubMed Web of Science ®Google Scholar
• Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, Richardson AL, Krop IE, Verselis SJ, Dillon DA, et al. Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat. 2013;139(1):193–98.
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Meo M, Vainio H. Risk factors for breast cancer, including occupational exposures. Saf Health Work.. 2011;2(1):1–8.
   PubMedGoogle Scholar
• Finn O. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(suppl_8):viii6–viii9. doi:10.1093/annonc/mds256.
   PubMed Web of Science ®Google Scholar
• Shore ND. Advances in the understanding of cancer immunotherapy. BJU Int. 2015;116(3):321–29. doi:10.1111/bju.12692.
   PubMed Web of Science ®Google Scholar
• Umar A. Cancer immunoprevention: a new approach to intercept cancer early. Cancer Prev Res. 2014 p. canprevres. 0213.2014;7(11):1067–71. doi:10.1158/1940-6207.CAPR-14-0213.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 2015 Dec;35 Suppl:S185–S198.
   Google Scholar
• Yang B, Jeang J, Yang A, Wu TC, Hung C-F. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10(11):3153–64. doi:10.4161/21645515.2014.980686.
   PubMed Web of Science ®Google Scholar
• Tiptiri-Kourpeti A, Spyridopoulou K, Pappa A, Chlichlia K. DNA vaccines to attack cancer: strategies for improving immunogenicity and efficacy. Pharmacol Ther. 2016;165:32–49. doi:10.1016/j.pharmthera.2016.05.004.
   PubMed Web of Science ®Google Scholar
• Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med. 2010;8(1):53. doi:10.1186/1479-5876-8-53.
   PubMedGoogle Scholar
• Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, Gao F, Gillanders WE, Mohanakumar T. Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ ICOS hi T cells. Breast Cancer Res Treat. 2013;138(1):109–18. doi:10.1007/s10549-012-2110-9.
   PubMed Web of Science ®Google Scholar
• de Paula Peres L, da Luz FAC, Dos Anjos Pultz B, Brígido PC, de Araújo RA, Goulart LR, Silva MJB. Peptide vaccines in breast cancer: the immunological basis for clinical response. Biotechnol Adv. 2015;33(8):1868–77. doi:10.1016/j.biotechadv.2015.10.013.
   PubMed Web of Science ®Google Scholar
• Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids. 2012;2012:967347. doi:10.1155/2012/967347.
   PubMedGoogle Scholar
• Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3(8):630. doi:10.1038/nri1150.
   PubMed Web of Science ®Google Scholar
• Vigneron N. Human tumor antigens and cancer immunotherapy. Biomed Res Int. 2015;2015:1–17. doi:10.1155/2015/948501.
   Web of Science ®Google Scholar
• Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. The Journal of Experimental Medicine. 1994;180(1):35–42. doi:10.1084/jem.180.1.35.
   PubMed Web of Science ®Google Scholar
• Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. The Journal of Experimental Medicine. 1996;183(3):1185–92. doi:10.1084/jem.183.3.1185.
   PubMed Web of Science ®Google Scholar
• Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. Embo J. 1987;6(3):605. doi:10.1002/j.1460-2075.1987.tb04797.x.
   PubMed Web of Science ®Google Scholar
• Demetris Iacovides SM, Achilleos C, Strati K. Shared mechanisms in stemness and carcinogenesis: lessons from oncogenic viruses. Front Cell Infect Microbiol. 2013;3. doi:10.3389/fcimb.2013.00072.
   PubMed Web of Science ®Google Scholar
• Lurquin C, De Smet C, Brasseur F, Muscatelli F, Martelange V, De Plaen E, Brasseur R, Monaco AP, Boon T. Two members of the humanmagebgene family located in Xp21. 3 are expressed in tumors of various histological origins. Genomics. 1997;46(3):397–408. doi:10.1006/geno.1997.5052.
   PubMed Web of Science ®Google Scholar
• Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001;61:5544–51.
   PubMed Web of Science ®Google Scholar
• Tarnowski M, Czerewaty M, Deskur A, Safranow K, Marlicz W, Urasińska E, Ratajczak MZ, Starzyńska T. Expression of cancer testis antigens in colorectal cancer: new prognostic and therapeutic implications. Dis Markers. 2016;2016:1–9. doi:10.1155/2016/1987505.
   Web of Science ®Google Scholar
• Wadle A, Kubuschok B, Imig J, Wuellner B, Wittig C, Zwick C, Mischo A, Waetzig K, Romeike BFM, Lindemann W, et al. Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer. 2006;119(1):117–25. doi:10.1002/ijc.21744.
   PubMed Web of Science ®Google Scholar
• Zajac P, Schultz-Thater E, Tornillo L, Sadowski C, Trella E, Mengus C, Iezzi G, Spagnoli GC. MAGE-A antigens and cancer immunotherapy. Front Med. 2017;4:18. doi:10.3389/fmed.2017.00018.
   Web of Science ®Google Scholar
• Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget. 2015;6(18):15772. doi:10.18632/oncotarget.4694.
   PubMedGoogle Scholar
• Neumann F, Wagner C, Preuss K-D, Kubuschok B, Schormann C, Stevanovic S, Pfreundschuh M. Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells. Blood. 2005;106(9):3105–13. doi:10.1182/blood-2005-04-1487.
   PubMed Web of Science ®Google Scholar
• Türeci O, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci. 1998;95(9):5211–16. doi:10.1073/pnas.95.9.5211.
   PubMed Web of Science ®Google Scholar
• Tammela J, Uenaka A, Ono T, Noguchi Y, Jungbluth AA, Mhawech-Fauceglia P, Qian F, Schneider S, Sharma S, Driscoll D, et al. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol. 2006;29(4):903–10.
   PubMed Web of Science ®Google Scholar
• Ono T, Kurashige T, Harada N, Noguchi Y, Saika T, Niikawa N, Aoe M, Nakamura S, Higashi T, Hiraki A, et al. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci. 2001;98(6):3282–87. doi:10.1073/pnas.041625098.
   PubMed Web of Science ®Google Scholar
• Costa Y, Speed R, Öllinger R, Alsheimer M, Semple CA, Gautier P, Maratou K, Novak I, Höög C, Benavente R and Cooke HJ, Two novel proteins recruited by synaptonemal complex protein 1 (SYCP1) are at the centre of meiosis. J Cell Sci. 2005;118(12):2755–62. doi:10.1242/jcs.02402.
   PubMed Web of Science ®Google Scholar
• Sahin U, Koslowski M, Türeci O, Eberle T, Zwick C, Romeike B, Moringlane JR, Schwechheimer K, Feiden W, Pfreundschuh M, et al. Expression of cancer testis genes in human brain tumors. Clin Cancer Res. 2000;6(10):3916–22.
   PubMed Web of Science ®Google Scholar
• Kubuschok B, Xie X, Jesnowski R, Preuss K-D, Romeike BFM, Neumann F, Regitz E, Pistorius G, Schilling M, Scheunemann P, et al. Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int J Cancer. 2004;109(4):568–75. doi:10.1002/ijc.20006.
   PubMed Web of Science ®Google Scholar
• Luo G, Huang S, Xie X, Stockert E, Chen YT, Kubuschok B, Pfreundschuh M. Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun Arch. 2002;2(1):11.
   PubMedGoogle Scholar
• Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K, Mori M. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer. 2001;85(5):713. doi:10.1054/bjoc.2001.1974.
   PubMed Web of Science ®Google Scholar
• Whitehurst AW, Xie Y, Purinton SC, Cappell KM, Swanik JT, Larson B, Girard L, Schorge JO, White MA. Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res. 2010;70(19):7652–61. doi:10.1158/0008-5472.
   PubMed Web of Science ®Google Scholar
• Salmaninejad A, Zamani MR, Pourvahedi M, Golchehre Z, Hosseini Bereshneh A, Rezaei N. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest. 2016;45(7):619–40. doi:10.1080/08820139.2016.1197241.
   PubMed Web of Science ®Google Scholar
• Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Marie Nicolay HJ, Sigalotti L, Maio M. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011;5(2):164–82. doi:10.1016/j.molonc.2011.02.001.
   PubMed Web of Science ®Google Scholar
• Tang C-T, Li P-C, Liu I-J, Liao M-Y, Chiu C-Y, Chao D-Y, Wu H-C. An epitope-substituted DNA vaccine improves safety and immunogenicity against dengue virus type 2. PLoS Negl Trop Dis. 2015;9(7):e0003903. doi:10.1371/journal.pntd.0003903.
   PubMed Web of Science ®Google Scholar
• Okuyama H, Tominaga A, Fukuoka S, Taguchi T, Kusumoto Y, Ono S. Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-γ. Oncol Rep. 2017;37(2):684–94. doi:10.3892/or.2017.5346.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–92. doi:10.1158/1078-0432.CCR-14-1860.
   PubMed Web of Science ®Google Scholar
• Song S, Wang F, He X, He Y, Li D, Sun S. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice. Vaccine. 2007;25(25):4853–60. doi:10.1016/j.vaccine.2006.12.029.
   PubMed Web of Science ®Google Scholar
• Mahdavi M, Mohabatkar H, Keyhanfar M, Dehkordi AJ, Rabbani M. Linear and conformational B cell epitope prediction of the HER 2 ECD-subdomain III by in silico methods. Asian Pac J Cancer Prev. 2012;13(7):3053–59. doi:10.7314/APJCP.2012.13.7.3053.
   PubMedGoogle Scholar
• Chen P, Rayner S, Hu K-H. Advances of bioinformatics tools applied in virus epitopes prediction. Virol Sin. 2011;26(1):1–7. doi:10.1007/s12250-011-3159-4.
   PubMedGoogle Scholar
• Safavi A, Kefayat A, Sotoodehnejadnematalahi F, Salehi M, Modarressi MH. In silico analysis of synaptonemal complex protein 1 (SYCP1) and acrosin binding protein (ACRBP) antigens to design novel multiepitope peptide cancer vaccine against breast cancer. Int J Pept Res Ther. 2018;25(4):1343–59.
   Web of Science ®Google Scholar
• Safavi A, Kefayat A, Sotoodehnejadnematalahi F, Salehi M, Modarressi MH. Production, purification, and in vivo evaluation of a novel multiepitope peptide vaccine consisted of immunodominant epitopes of SYCP1 and ACRBP antigens as a prophylactic melanoma vaccine. Int Immunopharmacol. 2019;76:105872. doi:10.1016/j.intimp.2019.105872.
   Google Scholar
• Arora P, Porcelli SAJJ. An efficient and high yield method for isolation of mouse dendritic cell subsets. J Vis Exp. 2016;(110):e53824. doi:10.3791/53824.
   Google Scholar
• Kefayat A, Ghahremani F, Motaghi H, Mehrgardi M. Investigation of different targeting decorations effect on the radiosensitizing efficacy of albumin-stabilized gold nanoparticles for breast cancer radiation therapy. Eur J Pharm Sci. 2019;130:225–33. doi:10.1016/j.ejps.2019.01.037.
   Google Scholar
• Bailey-Downs LC, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, Berry WL, Hurst RE, Ihnat MA. Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression. PLoS One. 2014;9(5):e98624. doi:10.1371/journal.pone.0098624.
   Google Scholar
• Safavi A, Kefayat A, Ghahremani F, Mahdevar E, Moshtaghian J. Immunization using male germ cells and gametes as rich sources of cancer/testis antigens for inhibition of 4T1 breast tumors’ growth and metastasis in BALB/c mice. Int Immunopharmacol. 2019;74:105719. doi:10.1016/j.intimp.2019.105719.
   Google Scholar
• Rajeh MAB, Kwan YP, Zakaria Z, Latha LY, Jothy SL, Sasidharan S. Acute toxicity impacts of Euphorbia hirta L extract on behavior, organs body weight index and histopathology of organs of the mice and Artemia salina. Pharmacogn Res. 2012;4(3):170.
   PubMedGoogle Scholar
• Ghahremani F, Kefayat A, Shahbazi-Gahrouei D, Motaghi H, Mehrgardi MA and Haghjooy-Javanmard S. AS1411 aptamer-targeted gold nanoclusters effect on the enhancement of radiation therapy efficacy in breast tumor-bearing mice. Nanomedicine. 2018;13(20):2563–78.
   PubMed Web of Science ®Google Scholar
• Ibrahim K, Al-Mutary M, Bakhiet A, Khan H. Histopathology of the liver, kidney, and spleen of mice exposed to gold nanoparticles. Molecules. 2018;23(8):E1848. doi:10.3390/molecules23081848.
   Google Scholar
• Smeltz RB, Chen J, Ehrhardt R, Shevach EM. Role of IFN-γ in Th1 differentiation: IFN-γ regulates IL-18Rα expression by preventing the negative effects of IL-4 and by inducing/maintaining IL-12 receptor β2 expression. J Immunol. 2002;168(12):6165–72. doi:10.4049/jimmunol.168.12.6165.
   PubMed Web of Science ®Google Scholar
• Bradley LM, Dalton DK, Croft M. A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol. 1996;157:1350–58.
   PubMed Web of Science ®Google Scholar
• Paludan S. Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship. Scand J Immunol. 1998;48(5):459–68. doi:10.1046/j.1365-3083.1998.00435.x.
   PubMed Web of Science ®Google Scholar
• Krishna S, Anderson KS. T-cell epitope discovery for therapeutic cancer vaccines. Vaccine Design. Methods Mol Biol. 2016;1403:779–96. doi:10.1007/978-1-4939-3387-7_45.
   Google Scholar
• Zhang H, Huang W. Fusion proteins of Hsp70 with tumor-associated antigen acting as a potent tumor vaccine and the C-terminal peptide-binding domain of Hsp70 being essential in inducing antigen-independent anti-tumor response in vivo. Cell Stress Chaperones. 2006;11(3):216. doi:10.1379/CSC-191R.1.
   PubMed Web of Science ®Google Scholar
• Lin -C-C, Chou C-W, Shiau A-L, Tu C-F, Ko T-M, Chen Y-L, Yang B-C, Tao M-H, Lai M-D. Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther. 2004;10(2):290–301. doi:10.1016/j.ymthe.2004.05.015.
   PubMed Web of Science ®Google Scholar
• Lu J, Higashimoto Y, Appella E, Celis E. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol. 2004;172(7):4575–82. doi:10.4049/jimmunol.172.7.4575.
   PubMed Web of Science ®Google Scholar
• Pulaski BA, Ostrand‐Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2000;39(1):20.2. 1–20.2. 16. doi:10.1002/0471142735.im2002s39.
   Google Scholar
• Kaur P, Nagaraja GM, Zheng H, Gizachew D, Galukande M, Krishnan S, Asea A. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer. 2012;12(1):120. doi:10.1186/1471-2407-12-120.
   PubMedGoogle Scholar
• Sivakumar S, Safhi MM, Kannadasan M, Sukumaran N. Vaccine adjuvants – current status and prospects on controlled release adjuvancity. Saudi Pharm J. 2011;19(4):197–206. doi:10.1016/j.jsps.2011.06.003.
   PubMed Web of Science ®Google Scholar
• Machluf N, Arnon R. Therapeutic MUC1-based cancer vaccine expressed in flagella-efficacy in an aggressive model of breast cancer. World J Vaccines. 2012;2(3):109. doi:10.4236/wjv.2012.23015.
   Google Scholar
• Miyako H, Kametani Y, Katano I, Ito R, Tsuda B, Furukawa A, Saito Y, Ishikawa D, Ogino K, Sasaki S, et al. Antitumor effect of new HER2 peptide vaccination based on B cell epitope. Anticancer Res. 2011;31(10):3361–68.
   PubMed Web of Science ®Google Scholar
• Gerdts V, Littel-van den Hurk SVD, Griebel PJ, Babiuk, LA. Use of animal models in the development of human vaccines. Future Microbiol. 2007;2(6):667–75.
   Google Scholar
• Overgaard NH, Fan TM, Schachtschneider KM, Principe DR, Schook LB and Jungersen G. Of mice, dogs, pigs, and men: choosing the appropriate model for Immuno-oncology research. ILAR J. 2018;59(3):247–62.
   PubMed Web of Science ®Google Scholar
• Wei W-Z, Jones RF, Juhasz C, Gibson H, Veenstra J. Evolution of animal models in cancer vaccine development. Vaccine. 2015;33(51):7401–07.
   PubMed Web of Science ®Google Scholar
• Lopes A, Vandermeulen, G and Préat V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res. 2019;38(1):146.
   PubMed Web of Science ®Google Scholar
• Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–64.
   PubMed Web of Science ®Google Scholar
• Andrechek ER, Nevins JRJJOMM. Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. J Mol Med. 2010;88(11):1095–100.
   PubMed Web of Science ®Google Scholar
• Seth R, Tai, LH, Falls, T, de Souza, CT, Bell, JC, Carrier, M, Atkins, H, Boushey, R and Auer, RA. Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model. Ann Surg. 2013;258(1):158–68.
   PubMed Web of Science ®Google Scholar
• Tai L-H, de Souza CT, Bélanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Ananth AA, Lam T, Breitbach CJ, Falls TJ. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 2013;73(1):97–107.
   PubMed Web of Science ®Google Scholar
• Ananth AA, Tai LH, Lansdell C, Alkayyal AA, Baxter KE, Angka L, Zhang J, de Souza CT, Stephenson KB, Parato K and Bramson, JL. Surgical stress abrogates pre-existing protective T cell mediated anti-tumor immunity leading to postoperative cancer recurrence. PLoS One. 2016;11(5).
   Web of Science ®Google Scholar
• Yakar I, Melamed R, Shakhar G, Shakhar K, Rosenne E, Abudarham N, Page GG, Ben-Eliyahu S. Prostaglandin E 2 suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann Surg Oncol. 2003;10(4):469.
   PubMed Web of Science ®Google Scholar
• Melamed R, Rosenne, E., Shakhar, K., Schwartz, Y., Abudarham, N. and Ben-Eliyahu, S. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a β-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Imm. 2005;19(2):114–26.
   PubMed Web of Science ®Google Scholar
• Maeng H, Terabe M, Berzofsky JAJCOII. Cancer vaccines: translation from mice to human clinical trials. Curr Opin Immunol. 2018;51:111–22.
   PubMed Web of Science ®Google Scholar
• Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6(1):1–11.
   PubMedGoogle Scholar